Business Context and Reporting Period
Company: The Cooper Companies, Inc. (COO)
Filing Type: Form 8-K (Current Report)
Date of Report: June 4, 2026
Reporting Period: Fiscal Second Quarter ended April 30, 2026
Business Overview: The Company operates two business units, including CooperSurgical, which manufactures medical products such as embryo culture media.
Key Financial Metrics and Material Changes
This filing primarily addresses a significant non-recurring litigation charge rather than standard quarterly operating results. Specific revenue, profit, cash flow, or margin figures for the quarter are not provided in this text; they are referenced in an attached press release.
- Net Litigation Charge: $271.6 million recorded in Selling, General and Administrative (SG&A) expenses.
- Accrued Litigation Liabilities: $324.1 million.
- Expected Insurance Recoveries: $52.5 million (offsetting the liability).
- Cash Flow Impact: The Company expects the majority of payments related to this charge to be made during fiscal 2026.
Management Commentary, Risks, and Unusual Items
CooperSurgical Product Recall and Litigation
In December 2023, CooperSurgical initiated a voluntary recall of three lots of LifeGlobal TM global embryo culture media. This led to claims alleging embryo loss or reduced viability.
- Current Status (as of June 4, 2026): Over 140 lawsuits filed (including three putative class actions, none certified) and over 1,500 claimants proffered.
- Resolution Progress: Settlement agreements have been reached covering over 95% of claimants.
- Reason for Charge: Management reassessed exposure due to procedural acceleration of cases, updated damage valuations, and increased defense costs. A loss was deemed probable and reasonably estimable, particularly regarding exposure exceeding insurance coverage.
Risks and Contingencies
The primary risk identified is the financial impact of the ongoing litigation related to the recalled product. While insurance covers a portion of the liability, the net charge reflects the estimated exposure beyond available coverage.
Investor Verification Checklist
- Verify the full text of the June 4, 2026 press release (Exhibit 99.1) for specific Q2 2026 revenue, earnings per share, and cash flow figures not detailed in this 8-K.
- Confirm the timeline and total amount of expected cash outflows for the $271.6 million net charge throughout fiscal 2026.
- Monitor the status of the three putative class actions to ensure no new certifications occur that could alter the settlement scope.
- Review the Company's insurance policy terms to understand the limits of the $52.5 million expected recovery and potential for further claims.